Belite Bio Inc

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Belite Bio Inc advances oral therapy for retinal diseases

Belite Bio Inc's financials show solid cash reserves and strategic investments in research, while clinical trials progress positively with enrollment milestones and upcoming data releases.
The company's focus on safety, efficacy, and market differentiation for their oral therapeutic presents both challenges and opportunities in a competitive landscape.
Overall, Belite Bio Inc's innovative approach to treating Stargardt disease and GA shows promise, supported by regulatory designations and a clear path for future growth.

Belite Bio Inc reports revenue growth and progresses in Phase III trials

Belite Bio Inc shows positive revenue growth and financial stability but faces challenges in trial enrollment and managing expenses.
Tinlarebant's designations and progress in Phase III trials offer promising opportunities for future growth and FDA approval.
Balancing innovation with financial sustainability will be crucial for Belite Bio Inc's long-term success in the biopharmaceutical industry.

Belite Bio Inc reports Q4 loss, eyes positive trial outcomes

Belite Bio Inc's Q4 2023 performance reflects ongoing investment in research and development, with a focus on advancing treatments for retinal diseases.
The company's financial stability and upcoming milestones in 2024 position it well for future growth and progress in clinical trials.
Challenges in trial management and data handling require careful navigation, while opportunities lie in presenting key findings and exploring treatment synergies.

Belite Bio advances novel treatment for retinal diseases, financials stable

Belite Bio's Q1 2024 earnings call highlighted progress with Tinlarebant, a promising treatment for Stargardt disease and Geographic Atrophy. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth and potential market success.

Belite Bio Inc progresses in Stargardt trials, maintains strong cash position

Belite Bio Inc's Q2 2024 earnings call highlighted advancements in Tinlarebant trials, positive Phase II study results, and a robust financial position despite reporting a net loss. The company's focus on addressing Stargardt disease with Tinlarebant presents promising opportunities for future growth and market approval.

Belite Bio reports progress in clinical trials and financial stability

Belite Bio's Q3 performance reflects positive clinical and financial outcomes, positioning the company well for future growth and innovation in ocular disease treatments.
While facing challenges in patient tolerance monitoring and trial operations, Belite Bio's strengths in balance sheet stability and therapeutic efficacy offer opportunities for market success and expansion.
With strategic leadership additions and ongoing clinical advancements, Belite Bio is poised to make significant strides in addressing unmet medical needs in Stargardt disease and geographic atrophy.

Belite Bio Inc reports Q4 loss, progresses well in Phase III trials

Belite Bio Inc's Q4 2024 earnings call highlighted increased R&D expenses, a net loss of $36.1 million, and positive advancements in Tinlarebant trials. Challenges include enrollment targets and addressing various trial-related queries. Opportunities lie in potential label expansions and future trial plans for Tinlarebant.

Belite Bio Inc (BLTE) excels in Q1 2025 with strong trial results and financial stability

Belite Bio Inc (BLTE) showcased strong performance in Tinlarebant trials and financial stability in Q1 2025, supported by a robust cash position. While facing challenges in regulatory processes and managing expenses, the company's positive interim trial results and regulatory designations position it well for future growth. With opportunities to attract partners, expedite development, and address medical needs, Belite Bio Inc (BLTE) is poised for continued success in the biopharmaceutical market.

Belite Bio Inc (BLTE) reports higher net loss but secures $15M funding for Tinlarebant trials

Belite Bio Inc (BLTE) reported a higher net loss in Q2 2025 but raised $15 million in a direct offering, ending the quarter with $149.2 million in cash. Tinlarebant's progress in Phase III trials for Stargardt's disease and geographic atrophy is promising. The company's strong balance sheet provides 4 years of cash runway, excluding commercialization costs.

Belite Bio advances clinical trials, secures funding for global expansion

Belite Bio's Q3 performance reflects progress in clinical trials, financial strength from successful fundraising, and strategic regulatory advancements. While facing challenges of expenses and profitability, the company is poised to leverage opportunities in upcoming trial data and market approvals. Maintaining a balance between investment in research, operational efficiency, and regulatory milestones will be key for sustained growth. Overall, Belite Bio's focus on innovation, financial stability, and global expansion positions it well for future success in the biopharmaceutical industry.

Belite Bio Inc reports strong 2025 performance and eyes global expansion

Belite Bio Inc (BLTE) made significant strides in 2025 with positive trial results and successful fundraising, positioning the company for future growth. While facing financial challenges and pricing strategy considerations, the company's strong cash reserves and strategic plans offer a foundation for success. Opportunities lie in upcoming regulatory submissions, product launches, and international partnerships, signaling potential for market expansion and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.